Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

OBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Peyrin-Biroulet, L, Sandborn, W, Sands, B, Reinisch, W, Bemelman, W, Bryant, R, D'Haens, G, Dotan, I, Dubinsky, M, Feagan, B, Fiorino, G, Gearry, R, Krishnareddy, S, Lakatos, P, Loftus, E, Marteau, P, Munkholm, P, Murdoch, T, Ordás, I, Panaccione, R, Riddell, R, Ruel, J, Rubin, D, Samaan, M, Siegel, C, Silverberg, MS, Stoker, J, Schreiber, S, Travis, S, Van Assche, G, Danese, S, Panes, J, Bouguen, G, O'Donnell, S, Pariente, B, Winer, S, Hanauer, S, Colombel, J
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	Nature Publishing Group 2015

Gelijkaardige items

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
door: Sandborn, W, et al.
Gepubliceerd in: (2016)

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.
door: Peyrin-Biroulet, L, et al.
Gepubliceerd in: (2012)

Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn’s disease: an IOIBD initiative
door: Danese, S, et al.
Gepubliceerd in: (2015)

Development of an index to define overall disease severity in IBD
door: Siegel, C, et al.
Gepubliceerd in: (2016)

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
door: D'Haens, G, et al.
Gepubliceerd in: (2009)

Biologic Therapies: From Complexity to Clinical Practice in a Changing Environment
door: Remo Panaccione, et al.
Gepubliceerd in: (2015-12-01)

Evolving concepts in Phase I and II Drug Development for Crohn's Disease.
door: Jairath, V, et al.
Gepubliceerd in: (2016)

Development of the Crohn's disease digestive damage score, the Lemann score.
door: Pariente, B, et al.
Gepubliceerd in: (2011)

Biomarker correlation with endoscopic outcomes in patients with Crohn's disease: data from CALM
door: Reinisch, W, et al.
Gepubliceerd in: (2018)

Evolving concepts in phases I and II drug development for Crohn's Disease
door: Jairath, V, et al.
Gepubliceerd in: (2016)

Standardizing scoring conventions for Crohn’s disease endoscopy: An international RAND/UCLA appropriateness study
door: Khanna, R, et al.
Gepubliceerd in: (2023)

The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis
door: Travis, S, et al.
Gepubliceerd in: (2013)

Biosimilars in IBD: hope or expectation?
door: Gecse, K, et al.
Gepubliceerd in: (2013)

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
door: Vuitton, L, et al.
Gepubliceerd in: (2017)

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
door: Clark, M, et al.
Gepubliceerd in: (2007)

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
door: Gasche, C, et al.
Gepubliceerd in: (2000)

Reliability and initial validation of the ulcerative colitis endoscopic index of severity.
door: Travis, S, et al.
Gepubliceerd in: (2013)

The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS].
door: Travis, S, et al.
Gepubliceerd in: (2015)

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
door: Panaccione, R, et al.
Gepubliceerd in: (2019)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
door: Travis, S, et al.
Gepubliceerd in: (2012)

Review article: defining remission in ulcerative colitis.
door: Travis, S, et al.
Gepubliceerd in: (2011)

European evidence-based Consensus on the management of ulcerative colitis: Current management.
door: Travis, S, et al.
Gepubliceerd in: (2008)

Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
door: Laurent Peyrin-Biroulet, et al.
Gepubliceerd in: (2024-01-01)

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
door: Sandborn, W, et al.
Gepubliceerd in: (2015)

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
door: Colombel, J, et al.
Gepubliceerd in: (2017)

CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease
door: Ma, C, et al.
Gepubliceerd in: (2022)

Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
door: Travis, S, et al.
Gepubliceerd in: (2017)

Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
door: Travis, S, et al.
Gepubliceerd in: (2017)

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
door: D'Haens, G, et al.
Gepubliceerd in: (2011)

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
door: Van Assche, G, et al.
Gepubliceerd in: (2011)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
door: Travis, S, et al.
Gepubliceerd in: (2014)

Budesonide MMX® for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis.
door: Lichtenstein, G, et al.
Gepubliceerd in: (2015)

Lymphoma risk and overall safety profile of Adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid
door: D'Haens, G, et al.
Gepubliceerd in: (2018)

Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM
door: Yzet, C, et al.
Gepubliceerd in: (2019)

Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.
door: Gottlieb, K, et al.
Gepubliceerd in: (2015)

The real-world global use of patient-reported outcomes for the care of patients with inflammatory bowel disease
door: Horrigan, JM, et al.
Gepubliceerd in: (2023)

Benzimidazoles promote anti-TNF mediated induction of regulatory macrophages and enhance therapeutic efficacy in a murine model
door: Wildenberg, M, et al.
Gepubliceerd in: (2017)

Antieosinophil Therapeutics
door: Straumann, A, et al.
Gepubliceerd in: (2013)

Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis
door: Samaan, MA, et al.
Gepubliceerd in: (2018)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA
door: Travis, S, et al.
Gepubliceerd in: (2017)